Quadrivalent HPV Vaccine
Aiweijia: China’s First Domestic Quadrivalent HPV Vaccine Completes Full Homegrown HPV Lineup
NMPA has approved China’s first domestic quadrivalent HPV vaccine (Aiweijia) from Sinopharm’s CNBG. Following the launch of domestic bivalent and nine-valent vaccines, and after Merck’s Gardasil, it is the second quadrivalent on the Chinese market, targeting HPV 6/11/16/18 for women aged 18–45.